{"title":"Shaping Allergy Training in the UK Foundation Programme: A National Survey.","authors":"Jennie Gane, Gillian Vance","doi":"10.1111/cea.14595","DOIUrl":"https://doi.org/10.1111/cea.14595","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sabrina Ghalili, Margaret Downes, Eden David, Ross O'Hagan, Grace Rabinowitz, Hannah Verma, Shayan Owji, Emma Guttman-Yassky, Benjamin Ungar
{"title":"Patch Testing Results From the Icahn School of Medicine at Mount Sinai Department of Dermatology 2017-2021.","authors":"Sabrina Ghalili, Margaret Downes, Eden David, Ross O'Hagan, Grace Rabinowitz, Hannah Verma, Shayan Owji, Emma Guttman-Yassky, Benjamin Ungar","doi":"10.1111/cea.14591","DOIUrl":"https://doi.org/10.1111/cea.14591","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hoang Kim Tu Trinh, Kieu-Minh Le, Thanh Niem Vo Van, Duy Le Pham, Hieu Thao Nguyen, Minh Nguyet Tran Thi, Bao Yen Pham, Dinh Minh Pham
Five potential allergens of freshwater crab (Somanniathelphusa sinensis), including hemocyanin, have been discovered. Specific IgE to haemocyanin was increased in crab-allergic than in crab-tolerant patients. The add-on of specific IgE to hemocyanin to skin prick test enhanced the specificity of the crab allergy diagnosis. IgE, immunoglobulin E; rHM, recombinant haemocyanin; sIgE, specific IgE; SPT: skin prick test.
{"title":"Comparison of Conventional IgE Assay and Measurement of Specific IgE to Haemocyanin for the Diagnosis of Adult Crab Allergy.","authors":"Hoang Kim Tu Trinh, Kieu-Minh Le, Thanh Niem Vo Van, Duy Le Pham, Hieu Thao Nguyen, Minh Nguyet Tran Thi, Bao Yen Pham, Dinh Minh Pham","doi":"10.1111/cea.14597","DOIUrl":"https://doi.org/10.1111/cea.14597","url":null,"abstract":"<p><p>Five potential allergens of freshwater crab (Somanniathelphusa sinensis), including hemocyanin, have been discovered. Specific IgE to haemocyanin was increased in crab-allergic than in crab-tolerant patients. The add-on of specific IgE to hemocyanin to skin prick test enhanced the specificity of the crab allergy diagnosis. IgE, immunoglobulin E; rHM, recombinant haemocyanin; sIgE, specific IgE; SPT: skin prick test.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rachel M. Childs, Robert J. Boyle, Victoria L. Sibson
<p>‘Growing up’ or ‘toddler’ milks (GUM), marketed for children aged 1–3 years and older, are widely recognised by health bodies as unnecessary and unhealthy. Public health advice is that breastmilk, water, cows' milk or another animal milk should be the main drink for young children from age 1 onwards. Manufacturers claim that GUM are an effective medium to deliver nutrients to young children, especially vitamin D, calcium and iron, which are commonly used to fortify GUM. But GUM are advised against, mainly due to their high free sugars content. UK data show that GUM are the main source of free sugars among those 12- to 18-month-old children who consume them, accounting for half of their total free sugars intake [<span>1</span>]. In 2011, 36% of children in this age group were GUM consumers. That figure is likely to have risen, because GUM sales are increasing worldwide. Globally, there was a more than twofold increase in GUM sales per child born, from 2005 through 2019 [<span>2</span>]. In the context of increasing overweight and obesity and high levels of dental decay in young children, increasing GUM sales represent a worrying trend. While marketing of infant formula suitable from 0 to 12 months is strictly regulated in many regions, GUM marketing for children over 12 months has very few restrictions. This is despite World Health Organization recommendations that inappropriate marketing of all commercial milk formulas aimed at children < 36 months old should be prohibited. The lack of regulations means that manufacturers are able to market GUM using misleading nutrition and health claims and in ways which cross-promote infant formula.</p><p>One GUM product category that has received much attention recently and appears to be growing in popularity is plant-based GUM. The increase in availability of plant-based GUM reflects a shift in consumption patterns in the general population—away from cows' milk, towards plant-based alternatives [<span>3</span>]. The nutrient content of plant-based GUM is a cause for concern. Some of the highest-sugar GUM available are plant-based, and a lack of labelling regulation means that consumers are often not aware of the high free sugars content. Indeed, plant-based GUM marketing may misleadingly suggest these products are low in sugar. For example, most oat milks contain free sugars, which are produced by the processing of the oats, where naturally present starch is broken down into sweet-tasting free sugars. This means that an oat milk can claim to have ‘no added sugars’, while containing even more free sugars than a standard cows' milk–based GUM.</p><p>Plant-based GUM have low nutritional value in terms of protein concentration or quality and certain micronutrients, compared with animal milks [<span>3</span>]. Thus, their role in young child feeding is uncertain, but there are clear health hazards associated with many plant-based GUM. In parallel with the shift towards plant-milk consumption, there is widesp
{"title":"Plant-Based and Dairy-Free Drinks: An Emerging Health Hazard for Young Children","authors":"Rachel M. Childs, Robert J. Boyle, Victoria L. Sibson","doi":"10.1111/cea.14589","DOIUrl":"10.1111/cea.14589","url":null,"abstract":"<p>‘Growing up’ or ‘toddler’ milks (GUM), marketed for children aged 1–3 years and older, are widely recognised by health bodies as unnecessary and unhealthy. Public health advice is that breastmilk, water, cows' milk or another animal milk should be the main drink for young children from age 1 onwards. Manufacturers claim that GUM are an effective medium to deliver nutrients to young children, especially vitamin D, calcium and iron, which are commonly used to fortify GUM. But GUM are advised against, mainly due to their high free sugars content. UK data show that GUM are the main source of free sugars among those 12- to 18-month-old children who consume them, accounting for half of their total free sugars intake [<span>1</span>]. In 2011, 36% of children in this age group were GUM consumers. That figure is likely to have risen, because GUM sales are increasing worldwide. Globally, there was a more than twofold increase in GUM sales per child born, from 2005 through 2019 [<span>2</span>]. In the context of increasing overweight and obesity and high levels of dental decay in young children, increasing GUM sales represent a worrying trend. While marketing of infant formula suitable from 0 to 12 months is strictly regulated in many regions, GUM marketing for children over 12 months has very few restrictions. This is despite World Health Organization recommendations that inappropriate marketing of all commercial milk formulas aimed at children < 36 months old should be prohibited. The lack of regulations means that manufacturers are able to market GUM using misleading nutrition and health claims and in ways which cross-promote infant formula.</p><p>One GUM product category that has received much attention recently and appears to be growing in popularity is plant-based GUM. The increase in availability of plant-based GUM reflects a shift in consumption patterns in the general population—away from cows' milk, towards plant-based alternatives [<span>3</span>]. The nutrient content of plant-based GUM is a cause for concern. Some of the highest-sugar GUM available are plant-based, and a lack of labelling regulation means that consumers are often not aware of the high free sugars content. Indeed, plant-based GUM marketing may misleadingly suggest these products are low in sugar. For example, most oat milks contain free sugars, which are produced by the processing of the oats, where naturally present starch is broken down into sweet-tasting free sugars. This means that an oat milk can claim to have ‘no added sugars’, while containing even more free sugars than a standard cows' milk–based GUM.</p><p>Plant-based GUM have low nutritional value in terms of protein concentration or quality and certain micronutrients, compared with animal milks [<span>3</span>]. Thus, their role in young child feeding is uncertain, but there are clear health hazards associated with many plant-based GUM. In parallel with the shift towards plant-milk consumption, there is widesp","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 11","pages":"852-854"},"PeriodicalIF":6.3,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14589","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alba Camino-Mera, Jacobo Pardo-Seco, Xabier Bello, Laura Argiz, Robert J. Boyle, Adnan Custovic, Jethro Herberg, Myrsini Kaforou, Stefania Arasi, Alessandro Fiocchi, Valentina Pecora, Simona Barni, Francesca Mori, Teresa Bracamonte, Luis Echeverria, Virginia O'Valle-Aísa, Noelia Lara Hernández-Martínez, Iria Carballeira, Emilio García, Carlos Garcia-Magan, José Domingo Moure-González, Purificación Gonzalez-Delgado, Teresa Garriga-Baraut, Sonsoles Infante, Gabriela Zambrano-Ibarra, Margarita Tomás-Pérez, Adrianna Machinena, Mariona Pascal, Ana Prieto, Sonia Vázquez-Cortes, Montserrat Fernández-Rivas, Leticia Vila, Laia Alsina, María José Torres, Giusi Mangone, Santiago Quirce, Federico Martinón-Torres, Marta Vázquez-Ortiz, Alberto Gómez-Carballa, Antonio Salas
The cover image is based on the article Whole Exome Sequencing Identifies Epithelial and Immune Dysfunction-Related Biomarkers in Food Protein-Induced Enterocolitis Syndrome by Alba Camino-Mera et al., https://doi.org/10.1111/cea.14564.
封面图片根据 Alba Camino-Mera 等人的文章《全外显子组测序发现食物蛋白诱发肠炎综合征的上皮细胞和免疫功能障碍相关生物标记物》（Whole Exome Sequencing Identifies Epithelial and Immune Dysfunction-Related Biomarkers in Food Protein-Induced Enterocolitis Syndrome）制作，https://doi.org/10.1111/cea.14564。
{"title":"Featured Cover","authors":"Alba Camino-Mera, Jacobo Pardo-Seco, Xabier Bello, Laura Argiz, Robert J. Boyle, Adnan Custovic, Jethro Herberg, Myrsini Kaforou, Stefania Arasi, Alessandro Fiocchi, Valentina Pecora, Simona Barni, Francesca Mori, Teresa Bracamonte, Luis Echeverria, Virginia O'Valle-Aísa, Noelia Lara Hernández-Martínez, Iria Carballeira, Emilio García, Carlos Garcia-Magan, José Domingo Moure-González, Purificación Gonzalez-Delgado, Teresa Garriga-Baraut, Sonsoles Infante, Gabriela Zambrano-Ibarra, Margarita Tomás-Pérez, Adrianna Machinena, Mariona Pascal, Ana Prieto, Sonia Vázquez-Cortes, Montserrat Fernández-Rivas, Leticia Vila, Laia Alsina, María José Torres, Giusi Mangone, Santiago Quirce, Federico Martinón-Torres, Marta Vázquez-Ortiz, Alberto Gómez-Carballa, Antonio Salas","doi":"10.1111/cea.14593","DOIUrl":"https://doi.org/10.1111/cea.14593","url":null,"abstract":"<p>The cover image is based on the article <i>Whole Exome Sequencing Identifies Epithelial and Immune Dysfunction-Related Biomarkers in Food Protein-Induced Enterocolitis Syndrome</i> by Alba Camino-Mera et al., https://doi.org/10.1111/cea.14564.\u0000\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"54 11","pages":"i"},"PeriodicalIF":6.3,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14593","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142641354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hye Kyu Min, Sooji Lee, Soeun Kim, Yejun Son, Jaeyu Park, Hyeon Jin Kim, Jinseok Lee, Hayeon Lee, Lee Smith, Masoud Rahmati, Jiseung Kang, Nikolaos G. Papadopoulos, Seong H. Cho, Jong Woo Hahn, Dong Keon Yon
<div> <section> <h3> Objective</h3> <p>Data on the global prevalence of chronic rhinosinusitis (CRS) is significantly varied and limited across countries and over time. Therefore, we aimed to conduct a comprehensive investigation into the global, regional, and national burden of CRS from the years 1980 to 2021, as well as identify those factors that influence levels of such burden.</p> </section> <section> <h3> Design</h3> <p>We conducted a systematic review and meta-analysis of general population-based observational studies focusing on CRS. We calculated pooled estimates of CRS prevalence and incidence with 95% confidence intervals (CIs). Subgroup analyses were conducted stratifying by sex, age cohorts, geographic regions, smoking status, obesity, and comorbid conditions.</p> </section> <section> <h3> Data Sources</h3> <p>PubMed/MEDLINE, EMBASE, CINAHL, Google Scholar, and Cochrane databases.</p> </section> <section> <h3> Eligibility Criteria for Selection</h3> <p>We included general population-based observational studies on CRS published from database inception through October 20, 2023.</p> </section> <section> <h3> Results</h3> <p>A total of 28 eligible studies, encompassing more than 237 million participants and 11,342,923 patients with CRS from 20 countries across four continents, were included in the analysis. Global pooled prevalence of CRS and CRS with nasal polyps (CRSwNP) was found to be 8.71% (95% CI, 6.69–11.33; number of studies, 20) and 0.65% (95% CI, 0.56–0.75; number of studies, 4), respectively. The prevalence of CRS was greater in Europe compared with North America, South America, and Asia; adults compared with children; smokers compared with never-smoker; those with obesity compared with normal weight; and those with comorbidities such as asthma, diabetes mellitus, eczema, and nasal septal deviation. Pooled prevalence of CRS increased from 1980 to 2020 (1980–2000: 4.72%; 95% CI, 2.12–10.49; 2014–2020: 19.40%; 95% CI, 12.12–31.07). Similar patterns were observed in CRS incidence.</p> </section> <section> <h3> Conclusions</h3> <p>Our study provides valuable insights into CRS prevalence and incidence across diverse demographic and clinical factors, highlighting its increasing global burden. The reported prevalence of CRS varies internationally, and may be increasing over time. To enhance data quality and comparability, standardization of reporting methodologies is imperative.</p> </section> <section>
{"title":"Global Incidence and Prevalence of Chronic Rhinosinusitis: A Systematic Review","authors":"Hye Kyu Min, Sooji Lee, Soeun Kim, Yejun Son, Jaeyu Park, Hyeon Jin Kim, Jinseok Lee, Hayeon Lee, Lee Smith, Masoud Rahmati, Jiseung Kang, Nikolaos G. Papadopoulos, Seong H. Cho, Jong Woo Hahn, Dong Keon Yon","doi":"10.1111/cea.14592","DOIUrl":"10.1111/cea.14592","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Data on the global prevalence of chronic rhinosinusitis (CRS) is significantly varied and limited across countries and over time. Therefore, we aimed to conduct a comprehensive investigation into the global, regional, and national burden of CRS from the years 1980 to 2021, as well as identify those factors that influence levels of such burden.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design</h3>\u0000 \u0000 <p>We conducted a systematic review and meta-analysis of general population-based observational studies focusing on CRS. We calculated pooled estimates of CRS prevalence and incidence with 95% confidence intervals (CIs). Subgroup analyses were conducted stratifying by sex, age cohorts, geographic regions, smoking status, obesity, and comorbid conditions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Data Sources</h3>\u0000 \u0000 <p>PubMed/MEDLINE, EMBASE, CINAHL, Google Scholar, and Cochrane databases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Eligibility Criteria for Selection</h3>\u0000 \u0000 <p>We included general population-based observational studies on CRS published from database inception through October 20, 2023.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 28 eligible studies, encompassing more than 237 million participants and 11,342,923 patients with CRS from 20 countries across four continents, were included in the analysis. Global pooled prevalence of CRS and CRS with nasal polyps (CRSwNP) was found to be 8.71% (95% CI, 6.69–11.33; number of studies, 20) and 0.65% (95% CI, 0.56–0.75; number of studies, 4), respectively. The prevalence of CRS was greater in Europe compared with North America, South America, and Asia; adults compared with children; smokers compared with never-smoker; those with obesity compared with normal weight; and those with comorbidities such as asthma, diabetes mellitus, eczema, and nasal septal deviation. Pooled prevalence of CRS increased from 1980 to 2020 (1980–2000: 4.72%; 95% CI, 2.12–10.49; 2014–2020: 19.40%; 95% CI, 12.12–31.07). Similar patterns were observed in CRS incidence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our study provides valuable insights into CRS prevalence and incidence across diverse demographic and clinical factors, highlighting its increasing global burden. The reported prevalence of CRS varies internationally, and may be increasing over time. To enhance data quality and comparability, standardization of reporting methodologies is imperative.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 ","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"55 1","pages":"52-66"},"PeriodicalIF":6.3,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Byung-Keun Kim, Min-Suk Yang, Upasna Srivastava, Shraddha Piparia, Rinku Sharma, Anshul Tiwari, Alvin Kho, Richard Wong, Juan C. Celedón, Scott T. Weiss, Michael McGeachie, Kelan Tantisira
Introduction
MicroRNAs (miRNAs) have been linked to allergic diseases but their effects on sensitisation to allergens in individuals with asthma are unknown. We aimed to identify miRNAs associated with house dust mite (HDM) sensitisation in childhood asthma.
Methods
Serum samples from 1126 children with asthma who participated in the Genetics of Asthma in Costa Rica Study (GACRS) were profiled for 304 miRNAs. We first divided according to HDM sensitisation and then tested whether miRNAs were differentially expressed (DE) between the two groups. Gene enrichment analysis for target genes of the DE miRNAs was then performed to identify potential causal pathways. Replication analysis was performed in the Childhood Asthma Management Program (CAMP), in which expression data of 258 miRNAs in 491 children were available. A mediation analysis was conducted to discern relationships between miRNA and phenotype differences according to HDM sensitisation in GACRS cohort.
Results
There were 906 (80.5%) and 220 (19.5%) subjects in the GACRS HDM+ and HDM– groups. Compared with HDM– participants, those in the HDM+ group were more likely to be severe in variables including pulmonary function, oral corticosteroid use and blood tests. A total of 17 miRNAs were DE (p < 0.05) between the two groups, with miR-642a-3p, let-7c-5p and miR-107 most significantly associated with HDM sensitisation. In CAMP, there were 39 DE miRNAs, and increased expression of miR-107 in HDM+ children was replicated in this cohort. In both GACRS and CAMP, the cadherin-binding pathway was enriched in an analysis of target genes for DE miRNA. In a mediation analysis, miR-107 showed significant indirect effects on eosinophil count and total IgE that were mediated by HDM sensitisation.
Conclusion
In children with asthma, miR-107 is associated with HDM sensitisation. Furthermore, miR-107 was indirectly associated with total IgE and eosinophil count through HDM sensitisation.
{"title":"MiR-107 and Its Association With House Dust Mite Sensitisation: Implications for Asthma","authors":"Byung-Keun Kim, Min-Suk Yang, Upasna Srivastava, Shraddha Piparia, Rinku Sharma, Anshul Tiwari, Alvin Kho, Richard Wong, Juan C. Celedón, Scott T. Weiss, Michael McGeachie, Kelan Tantisira","doi":"10.1111/cea.14590","DOIUrl":"10.1111/cea.14590","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>MicroRNAs (miRNAs) have been linked to allergic diseases but their effects on sensitisation to allergens in individuals with asthma are unknown. We aimed to identify miRNAs associated with house dust mite (HDM) sensitisation in childhood asthma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Serum samples from 1126 children with asthma who participated in the Genetics of Asthma in Costa Rica Study (GACRS) were profiled for 304 miRNAs. We first divided according to HDM sensitisation and then tested whether miRNAs were differentially expressed (DE) between the two groups. Gene enrichment analysis for target genes of the DE miRNAs was then performed to identify potential causal pathways. Replication analysis was performed in the Childhood Asthma Management Program (CAMP), in which expression data of 258 miRNAs in 491 children were available. A mediation analysis was conducted to discern relationships between miRNA and phenotype differences according to HDM sensitisation in GACRS cohort.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There were 906 (80.5%) and 220 (19.5%) subjects in the GACRS HDM+ and HDM– groups. Compared with HDM– participants, those in the HDM+ group were more likely to be severe in variables including pulmonary function, oral corticosteroid use and blood tests. A total of 17 miRNAs were DE (<i>p</i> < 0.05) between the two groups, with miR-642a-3p, let-7c-5p and miR-107 most significantly associated with HDM sensitisation. In CAMP, there were 39 DE miRNAs, and increased expression of miR-107 in HDM+ children was replicated in this cohort. In both GACRS and CAMP, the cadherin-binding pathway was enriched in an analysis of target genes for DE miRNA. In a mediation analysis, miR-107 showed significant indirect effects on eosinophil count and total IgE that were mediated by HDM sensitisation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In children with asthma, miR-107 is associated with HDM sensitisation. Furthermore, miR-107 was indirectly associated with total IgE and eosinophil count through HDM sensitisation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"55 1","pages":"67-74"},"PeriodicalIF":6.3,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.14590","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Coco Dekkers, Hidde Smits, Dora Stölzl, Lotte Spekhorst, Edward Knol, Femke van Wijk, Inken Harder, Thomas Werfel, Jochen Schmitt, Andreas Kleinheinz, Susanne Abraham, Judith Thijs, Stephan Weidinger, Marjolein de Bruin-Weller, Daphne Bakker, Julia Drylewicz
<p>Treatment of atopic dermatitis (AD) is advancing towards more personalised medicine with novel therapies targeting specific immune pathways. Endotyping is important to identify patients who will benefit most from certain therapies [<span>1</span>]. Previously, we stratified AD patients into four clusters, of which two were defined as Type 2(T2)-dominant and the other two as T2 non-dominant [<span>2, 3</span>]. As dupilumab specifically targets the T2 pathway by inhibiting IL-4/IL-13 signalling, it is often assumed that patients assigned to a T2-dominant cluster would respond better to dupilumab. This study investigated serum protein profiles in AD patients with different responses to dupilumab and assessed the role of serum proteins in predicting treatment response.</p><p>Adult dupilumab-treated AD patients participating in the BioDay- or TREATgermany registries, and who provided written informed consent for data extraction, were screened for inclusion. Both registries are prospective, containing daily practice data regarding novel therapies for AD (ClinicalTrials.gov identifiers BioDay/TREAT:NCT03549416/NCT03057860) and have ethics committee approval (BioDay:METC 18-239/TREAT:No. EK TUD 118032016). Included patients, all with a baseline Eczema Area and Severity Index (EASI) ≥ 12, were categorised based on their treatment response at the first follow-up visit (12–16 weeks) compared to baseline as follows: improvement of the EASI of at least 90% (EASI ≥ 90), improvement of at least 75% but less than 90% (EASI ≥ 75) and improvement less than 50% (EASI < 50). Additionally, the EASI was collected after 24–28 and 52 weeks of treatment. For each patient, concentrations of 60 candidate AD biomarker proteins were measured in baseline serum samples and for a subgroup of patients at 12–16 weeks by using Luminex technology. Baseline protein concentrations were compared between response groups and clusters were defined using principal component analysis followed by K-means clustering. Random forest (RF) models trained on baseline data were used to assess cluster stability during treatment and to determine if treatment response can be predicted.</p><p>A total of 127 patients were selected, with a median age of 46.7 years (IQR: 31.4–60.3) and median baseline EASI of 19.4 (IQR: 15.6–27.3). Forty-seven patients were grouped in EASI ≥ 90, 49 in EASI ≥ 75 and 31 in EASI < 50. Only HGF (Hepatocyte Growth Factor) at baseline was significantly different between the response groups (<i>p</i> = 0.03), with higher concentrations in the EASI < 50 group compared to the EASI ≥ 90 group. A RF model trained to predict treatment response achieved an accuracy of only 35%, suggesting that the measured baseline proteins are not predictive of response in our cohort. Based on the expression pattern of the measured baseline proteins, a T2-dominant and non-dominant clusters were identified (Figure 1), which constituted of 22.8% and 77.2% of patients, respectively. Thirty
{"title":"Type 2 Immune-Dominant Endotype Is Not Associated With Increased Responsiveness to Dupilumab Treatment in Adult Atopic Dermatitis Patients","authors":"Coco Dekkers, Hidde Smits, Dora Stölzl, Lotte Spekhorst, Edward Knol, Femke van Wijk, Inken Harder, Thomas Werfel, Jochen Schmitt, Andreas Kleinheinz, Susanne Abraham, Judith Thijs, Stephan Weidinger, Marjolein de Bruin-Weller, Daphne Bakker, Julia Drylewicz","doi":"10.1111/cea.14585","DOIUrl":"10.1111/cea.14585","url":null,"abstract":"<p>Treatment of atopic dermatitis (AD) is advancing towards more personalised medicine with novel therapies targeting specific immune pathways. Endotyping is important to identify patients who will benefit most from certain therapies [<span>1</span>]. Previously, we stratified AD patients into four clusters, of which two were defined as Type 2(T2)-dominant and the other two as T2 non-dominant [<span>2, 3</span>]. As dupilumab specifically targets the T2 pathway by inhibiting IL-4/IL-13 signalling, it is often assumed that patients assigned to a T2-dominant cluster would respond better to dupilumab. This study investigated serum protein profiles in AD patients with different responses to dupilumab and assessed the role of serum proteins in predicting treatment response.</p><p>Adult dupilumab-treated AD patients participating in the BioDay- or TREATgermany registries, and who provided written informed consent for data extraction, were screened for inclusion. Both registries are prospective, containing daily practice data regarding novel therapies for AD (ClinicalTrials.gov identifiers BioDay/TREAT:NCT03549416/NCT03057860) and have ethics committee approval (BioDay:METC 18-239/TREAT:No. EK TUD 118032016). Included patients, all with a baseline Eczema Area and Severity Index (EASI) ≥ 12, were categorised based on their treatment response at the first follow-up visit (12–16 weeks) compared to baseline as follows: improvement of the EASI of at least 90% (EASI ≥ 90), improvement of at least 75% but less than 90% (EASI ≥ 75) and improvement less than 50% (EASI < 50). Additionally, the EASI was collected after 24–28 and 52 weeks of treatment. For each patient, concentrations of 60 candidate AD biomarker proteins were measured in baseline serum samples and for a subgroup of patients at 12–16 weeks by using Luminex technology. Baseline protein concentrations were compared between response groups and clusters were defined using principal component analysis followed by K-means clustering. Random forest (RF) models trained on baseline data were used to assess cluster stability during treatment and to determine if treatment response can be predicted.</p><p>A total of 127 patients were selected, with a median age of 46.7 years (IQR: 31.4–60.3) and median baseline EASI of 19.4 (IQR: 15.6–27.3). Forty-seven patients were grouped in EASI ≥ 90, 49 in EASI ≥ 75 and 31 in EASI < 50. Only HGF (Hepatocyte Growth Factor) at baseline was significantly different between the response groups (<i>p</i> = 0.03), with higher concentrations in the EASI < 50 group compared to the EASI ≥ 90 group. A RF model trained to predict treatment response achieved an accuracy of only 35%, suggesting that the measured baseline proteins are not predictive of response in our cohort. Based on the expression pattern of the measured baseline proteins, a T2-dominant and non-dominant clusters were identified (Figure 1), which constituted of 22.8% and 77.2% of patients, respectively. Thirty","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"55 1","pages":"97-99"},"PeriodicalIF":6.3,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707302/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hugo W F Mak, Elaine Lee, Jane C Y Wong, Philip H Li
{"title":"Psychometric Validation of the Traditional Chinese Chronic Urticaria Quality of Life Questionnaire.","authors":"Hugo W F Mak, Elaine Lee, Jane C Y Wong, Philip H Li","doi":"10.1111/cea.14586","DOIUrl":"https://doi.org/10.1111/cea.14586","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Suneela Zaigham, Nils Oskar Jõgi, Robert Movérare, Anders Sjölander, Niclas Rydell, Magnus Molin, Christer Janson, Andrei Malinovschi
<p>Eosinophilic inflammation in asthma is related to disease severity, lung function decline, disease control and response to corticosteroids during exacerbations [<span>1-3</span>]. Eosinophil activation leads to the release of cytokines, lipid mediators, chemotactic polypeptides and cytotoxic proteins that promote a pro-inflammatory host response and neutralises pathogens [<span>4</span>]. One of the cytotoxic granule proteins released during degranulation of activated eosinophils is the eosinophil-derived neurotoxin (EDN). Serum EDN is emerging as a novel marker of eosinophilic inflammation in patients with asthma [<span>4</span>]. In order to implement serum EDN as a marker in clinical practice, determinants and reference ranges for EDN need to be clearly established. Recently, EDN reference values were defined in early childhood [<span>5</span>]; however, further large studies defining values in older adults are needed. We aimed to study determinants of EDN using the Swedish CArdioPulmonary bioImage Study (SCAPIS), a general population study of middle-aged adults and propose reference values for EDN, including the lower (LLN) and upper limit of normal (ULN), in a healthy sub-population.</p><p>The Swedish CArdioPulmonary bioImage Study is a national, multicentred, population-based study of randomly selected men and women aged 50–64 years. Nationally, 30,154 men and women participated and from the Uppsala cohort 5036 subjects [<span>6</span>]. Serum EDN was an add-on measurement in the Uppsala cohort of SCAPIS (<i>n</i> = 4916) and was measured using an ImmunoCAP EDN research assay as described elsewhere [<span>7</span>]. EDN values were log-transformed for analysis. Univariate analyses were carried out to assess determinants of EDN, including age, sex, lifestyle, clinical conditions (assessed via questionnaire) and laboratory data. Independent sample <i>t</i>-tests were used to obtain mean values of EDN by each potential determining factor. The <i>p</i>-values were adjusted for false discovery rate (FDR) using the Benjamini–Hochberg method. Multiple linear regression models were used to assess the effect of determining factors on EDN. To define normal values of EDN, we selected a healthy population based on subjects free from EDN-modifying conditions. In this healthy sub-cohort, we used the 5<sup>th</sup> (LLN), 50<sup>th</sup> (median), 75<sup>th</sup>, 90<sup>th</sup> and 95<sup>th</sup> (ULN) percentiles to determine reference levels for serum EDN.</p><p>Male sex, body mass index (BMI) > 25, current smoking, presence of atopy, ever asthma, allergic rhinitis, angina pectoris, heart failure, hypertension, diabetes and impaired kidney function were all associated with higher mean EDN levels. Both pre-bronchodilatory FEV<sub>1</sub> < LLN and a post-bronchodilatory FEV<sub>1</sub>/FVC ratio < 0.70 were associated with higher mean EDN levels. After adjusting the <i>p</i>-values for FDR, these determining factors remained significantly
{"title":"Eosinophil-Derived Neurotoxin Determinants and Reference Values in a Swedish Middle-Aged General Population","authors":"Suneela Zaigham, Nils Oskar Jõgi, Robert Movérare, Anders Sjölander, Niclas Rydell, Magnus Molin, Christer Janson, Andrei Malinovschi","doi":"10.1111/cea.14579","DOIUrl":"10.1111/cea.14579","url":null,"abstract":"<p>Eosinophilic inflammation in asthma is related to disease severity, lung function decline, disease control and response to corticosteroids during exacerbations [<span>1-3</span>]. Eosinophil activation leads to the release of cytokines, lipid mediators, chemotactic polypeptides and cytotoxic proteins that promote a pro-inflammatory host response and neutralises pathogens [<span>4</span>]. One of the cytotoxic granule proteins released during degranulation of activated eosinophils is the eosinophil-derived neurotoxin (EDN). Serum EDN is emerging as a novel marker of eosinophilic inflammation in patients with asthma [<span>4</span>]. In order to implement serum EDN as a marker in clinical practice, determinants and reference ranges for EDN need to be clearly established. Recently, EDN reference values were defined in early childhood [<span>5</span>]; however, further large studies defining values in older adults are needed. We aimed to study determinants of EDN using the Swedish CArdioPulmonary bioImage Study (SCAPIS), a general population study of middle-aged adults and propose reference values for EDN, including the lower (LLN) and upper limit of normal (ULN), in a healthy sub-population.</p><p>The Swedish CArdioPulmonary bioImage Study is a national, multicentred, population-based study of randomly selected men and women aged 50–64 years. Nationally, 30,154 men and women participated and from the Uppsala cohort 5036 subjects [<span>6</span>]. Serum EDN was an add-on measurement in the Uppsala cohort of SCAPIS (<i>n</i> = 4916) and was measured using an ImmunoCAP EDN research assay as described elsewhere [<span>7</span>]. EDN values were log-transformed for analysis. Univariate analyses were carried out to assess determinants of EDN, including age, sex, lifestyle, clinical conditions (assessed via questionnaire) and laboratory data. Independent sample <i>t</i>-tests were used to obtain mean values of EDN by each potential determining factor. The <i>p</i>-values were adjusted for false discovery rate (FDR) using the Benjamini–Hochberg method. Multiple linear regression models were used to assess the effect of determining factors on EDN. To define normal values of EDN, we selected a healthy population based on subjects free from EDN-modifying conditions. In this healthy sub-cohort, we used the 5<sup>th</sup> (LLN), 50<sup>th</sup> (median), 75<sup>th</sup>, 90<sup>th</sup> and 95<sup>th</sup> (ULN) percentiles to determine reference levels for serum EDN.</p><p>Male sex, body mass index (BMI) > 25, current smoking, presence of atopy, ever asthma, allergic rhinitis, angina pectoris, heart failure, hypertension, diabetes and impaired kidney function were all associated with higher mean EDN levels. Both pre-bronchodilatory FEV<sub>1</sub> < LLN and a post-bronchodilatory FEV<sub>1</sub>/FVC ratio < 0.70 were associated with higher mean EDN levels. After adjusting the <i>p</i>-values for FDR, these determining factors remained significantly ","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"55 1","pages":"91-93"},"PeriodicalIF":6.3,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：